NCT03565913View on ClinicalTrials.gov

Potential Therapeutic Role of Effervescent Calcium-Magnesium Citrate in Chronic Kidney Disease Stage V

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL

Enrollment

269

Participants

Timeline

Start Date

January 22, 2017

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

CKD Stage 5

Interventions

DRUG

EffCaMgCit

Patients in the EffCaMgCit group will receive 45 meq (900 mg) Ca, 30 meq (365 mg) Mg, and 135 meq total citrate per day from 3 months to 2 years.

OTHER

CaAcS

CaAcS group will take 45 meq (900 mg) Ca and 45 meq acetate (without Mg or citrate), three times daily for 2 years

Trial Locations (1)

75224

DaVita Dialysis Centers, Dallas

All Listed Sponsors

lead

University of Texas Southwestern Medical Center

OTHER

NCT03565913 - Potential Therapeutic Role of Effervescent Calcium-Magnesium Citrate in Chronic Kidney Disease Stage V | Biotech Hunter | Biotech Hunter